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Case report
Cervical clear cell adenocarcinoma with an exceptionally low proliferation
index: Report of a case
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1. Background
Cervical clear cell adenocarcinoma (CCCA) is a rare malignancy
constituting approximately 4% of cervical adenocarcinomas. It has
historically occurred in the ectocervix of young women (teens to
twenties) with in utero exposure to diethylstilbestrol (DES), a medica-
tion used to prevent pregnancy complications until 1971 (Loureiro and
Oliva, 2014). Non-DES CCCA is associated with a bimodal distribution,
arising in both the ecto- and endocervix of women in their 20s and 70s
(Yang et al., 2017). It does not appear to be an HPV-driven malignancy,
with the only clear risk factors being adenosis and endometriosis of the
cervix as well as cervical tubo-endometrioid metaplasia (Loureiro and
Oliva, 2014).
CCCA is a highly malignant cancer characterized by a high Ki-67
proliferation index and a prognosis similar to stage-matched squamous
cell cervical cancer (Ju et al., 2017). With a 91% survival rate at 3 years
for stage I CCCA and a rapid decline in survival to 22% at 3 years if
advanced stage, CCCA is associated with late recurrence within gyne-
cologic organs as well as distant metastasis including to the peritoneum
and lungs (Thomas et al., 2008; Jones et al., 1993). CCCA can be
confused with several benign mimics including microglandular hyper-
plasia, mesonephric hyperplasia and lobular endocervical glandular
hyperplasia amongst others (Loureiro and Oliva, 2014).
While most of the mimics of CCCA, including mesonephric adeno-
carcinoma and gastric-type endocervical adenocarcinoma, have an as-
sociated non-malignant counterpart, to date there has been no benign
counterpart ascribed to CCCA (Loureiro and Oliva, 2014) (Mikami and
McCluggage, 2013).
We report on a woman who presented with atypical glandular cells
on Pap screening and was ultimately diagnosed with CCCA after un-
dergoing a biopsy and two cervical conization procedures. Findings on
her initial surgical specimen showed an extremely low-grade tumor,
illustrating the diagnostic diﬃculty of CCCA, and possibly representing
a benign counterpart or precursor.
2. Case
Written consent was provided and is available upon request. A 41-
year-old woman (gravida 1, para 1) with abnormal uterine bleeding
was found to have atypical glandular cells on Pap test, with negative
HPV co-testing and a benign endometrial biopsy. A transvaginal ultra-
sound revealed a simple ovarian cyst with otherwise normal uterus and
adnexa. Subsequent colposcopy with biopsy was interpreted as an
atypical glandular proliferation, with a note that the ﬁndings could be
concerning for clear cell carcinoma.
Due to lack of a deﬁnitive diagnosis, she proceeded to a loop elec-
trosurgical excision procedure (LEEP). The LEEP biopsy displayed a
tubulocystic proliferation involving all margins. The architecture of the
proliferation was a mixture of simple-appearing glands of variable size
(Fig. 1A). The simple glands were lined by a single layer of incon-
spicuous cells, lacking nuclear atypia and without apparent eosino-
philic or clear cytoplasmic inclusions; the glands contained strongly
eosinophilic secretions (Fig. 1B). Some cells lining the glands had more
prominent nuclei and an increased nuclear-to-cytoplasmic ratio
(Fig. 1C). No nucleoli were apparent. There was focal evidence of
hobnailing. A few areas showed intracystic papillary structures lined by
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atypical cells, with hyalinized stromal cores (Fig. 1D). No eosinophilic
or clear cytoplasmic inclusions were visible and very few mitotic ﬁgures
were present.
Due to the overall benign appearance of the lesion, microglandular
hyperplasia, lobular endocervical glandular hyperplasia and meso-
nephric hyperplasia were considered as possible diagnoses. The focal
presence of papillary structures with hobnailing and atypical nuclei,
however, raised concern for clear cell carcinoma.
Immunostains were performed (Fig. 2 and Table 1). Stains for es-
trogen (Fig. 2A) and progesterone receptors were negative, essentially
ruling out a diagnosis of microglandular hyperplasia, which the lit-
erature suggests is either concomitantly estrogen and progesterone re-
ceptor-positive (ER+/PR+) or ER+/PR–. Staining for TTF-1
(McFarland et al., 2016) and GATA-3 (Roma et al., 2015), two stains
often positive in mesonephric lesions, was negative. The specimen was
weakly androgen receptor-positive, which is typical of cervical tissue,
but tends to be lost in mesonephric adenocarcinoma (Silver et al., 2001;
Wani et al., 2008). Notably the biopsy was p16-negative, essentially
ruling out an HPV-associated malignancy. p53 (Fig. 2B) showed a wild-
type pattern with occasional positive cells, not diﬀusely positive as is
Fig. 1. (A) Low-power photomicrograph of clear cell lesion
in LEEP specimen (original magniﬁcation 20×). (B) Low-
power photomicrograph illustrating cysts lined by bland,
ﬂattened cells, with eosinophilic luminal secretions
(100×). (C) Rare cells with higher nuclear-to-cytoplasmic
ratio and atypical nuclear features (200×). (D) Intracystic
papillary projections (200×).
Fig. 2. Representative immunostains performed on the
LEEP specimen. (A) ER (original magniﬁcation 400×). (B)
p53 (200×). (C) Napsin A (200×). (D) Ki-67 (100×).
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typically associated with clear cell adenocarcinoma (Loureiro and
Oliva, 2014). Napsin A (Fig. 2C), typically positive in gynecologic clear
cell adenocarcinoma, and Bcl-2, positive in either clear cell adeno-
carcinoma or mesonephric lesions, were both positive. Ki-67 (Fig. 2D)
indicated a low proliferation index of< 1%, which is atypical in ra-
pidly growing lesions and not consistent with any histotype of adeno-
carcinoma (Pavlakis et al., 2010). Ki-67-positive cells were present only
at the periphery of the lesion, while the center of the lesion was ne-
gative.
While the histologic and immunohistochemical ﬁndings (particu-
larly clear Napsin A positivity) were concerning for clear cell adeno-
carcinoma, the low mitotic and proliferative activity and wild-type p53
staining were suggestive of a potentially less malignant lesion that
might be captioned as clear cell hyperplasia (an entity not speciﬁcally
described in the literature) or another glandular proliferation with clear
cell phenotype. A diagnosis of “glandular proliferation with clear cell
features” was rendered, with concern noted for CCCA. The margins of
excision were extensively positive, and more deﬁnitive classiﬁcation
was felt to require examining the edges of the lesion.
A second cone excision was performed. This specimen showed si-
milar ﬁndings with negative margins, and underlined the expansile,
non-inﬁltrative nature of the process, with rare smaller, inﬁltrative
glands at the perimeter. Given the size of the lesion (7 mm in width and
5 mm in depth in the largest specimen), and the lack of any other
suitable nosologic category, a diagnosis of CCCA was felt to best de-
scribe the process, but note was made of the unusual features.
In the absence of literature to support treatment of CCCA with only
cone excision, minimally invasive radical hysterectomy was performed
and showed no residual tumor. No adjuvant treatment was pursued.
The patient developed a postoperative deep vein thrombus (DVT) and
was placed on enoxaparin for 6 months. Follow-up was otherwise un-
eventful at 3 months. No further follow-up data were available due to
the short time elapsed.
3. Discussion
We report on the histology from a woman with abnormal uterine
bleeding, who was found to have atypical glandular cells of unknown
signiﬁcance on Pap. Subsequent surgical specimens, while concerning
for cervical clear cell adenocarcinoma by morphology and im-
munoproﬁle, appear to show a process with low malignant potential. Of
some interest, the patient experienced a postoperative DVT, which is
common in patients with clear cell carcinoma. Due to the low pro-
liferation index (Ki-67 < 1%), uneventful oncologic follow-up is an-
ticipated, although only a short follow-up interval has elapsed at pre-
sent. The distribution of proliferating cells only at the periphery of the
lesion is a phenomenon we have not previously observed and that has
not been extensively discussed in the literature. It may imply that the
lesion has a propensity for maturation or self-limitation.
Cervical clear cell carcinoma comprises approximately 4% of all
cervical adenocarcinomas, aﬀecting early reproductive age women as
well as post-menopausal women. Non-DES related CCCA has a prog-
nosis similar to that of cervical squamous cell carcinoma as well as
other cervical adenocarcinomas. Due to its rarity and therefore lack of
evidence to speciﬁcally guide treatment, it is currently treated similarly
to cervical squamous cell carcinoma (Thomas et al., 2008). There are no
systematic reports of treatment less than hysterectomy.
Cervical squamous cell carcinoma has a well-known precursor le-
sion, as do many types of adenocarcinoma, such as cervical adeno-
carcinoma NOS (adenocarcinoma in situ), mesonephric adenocarci-
noma (mesonephric hyperplasia) and gastric type endocervical
adenocarcinoma (lobular endocervical glandular hyperplasia) (Mikami
and McCluggage, 2013; Zaino, 2000). To date, no premalignant ana-
logue of cervical clear cell adenocarcinoma has been described. We
propose that the pathology in this patient may be indicative of a benign
or premalignant analogue (i.e., a forme fruste) of cervical clear cellTa
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adenocarcinoma. Further studies are mandatory before such an entity
(putatively best classiﬁed as clear cell hyperplasia) can be deﬁned.
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